Genomics and Personalized Medicine Act of 2006
The source supplies the latest action, but no lifecycle stage.
Latest action (3 Aug 2006): Read twice and referred to the Committee on Finance.
What this bill does
This bill, the Genomics and Personalized Medicine Act of 2006, aims to advance the field of personalized medicine. It would establish a working group within the Department of Health and Human Services to coordinate genetics and genomics research and its application in healthcare. The bill also calls for expanded research into genetic and environmental interactions, particularly concerning minority populations, and seeks to improve the quality and availability of training for genetics and genomics professionals.
Additionally, the legislation proposes a tax credit for research expenses related to developing specific diagnostic tests for drugs. It also intends to expand adverse event reporting to include those arising from genetic testing and to improve the safety and effectiveness of genetic tests themselves. The bill affects health professionals, researchers, and patients by aiming to improve the understanding and use of genetic information in healthcare.
This bill was introduced in the Senate in August 2006 and is currently in the committee phase. Further action would require it to be reported out of committee, passed by both the Senate and the House of Representatives, and then signed into law by the President.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Genomics and Personalized Medicine Act of 2006 - Requires the Secretary of Health and Human Services to: (1) establish the Genomics and Personalized Medicine Interagency Working Group to expand and accelerate genetics and genomics research and translate such research into clinical and public health applications; (2) expand and accelerate research and programs to collect genetic and genomic data that will advance the field of genomics and personalized medicine; (3) develop a plan for a national biobanking research initiative; (4) expand efforts to increase knowledge about the interaction between genetics and the environment and about ways in which molecular genetic screening, diagnostics, and treatments may be used to improve the health and health care of racial and ethnic minority populations; (5) increase recruitment and retention of trainees in genetics and genomics; (6) ensure the adequacy of genetics and genomics training for diagnosis, treatment, and counseling of adults and children for both rare and common disorders; (7) improve the safety, efficacy, and availability of information about genetic tests; and (8) improve the oversight and regulation of genetic tests.
Provides for the recruitment of health professionals from diverse backgrounds in the genomics workforce and improvement in the quality of genomics training.
Amends the Internal Revenue Code to establish a tax credit for qualified research expenses for the development of a qualified companion diagnostic test designed to provide information to increase the safety or effectiveness of a drug.
Provides for the expansion of adverse event reporting systems to encompass reports of adverse events resulting from genetic testing.
Timeline
3 Aug 2006
Read twice and referred to the Committee on Finance.
Common questions
- What does S. 3822 do?
- This bill, the Genomics and Personalized Medicine Act of 2006, aims to advance the field of personalized medicine. It would establish a working group within the Department of Health and Human Services to coordinate genetics and genomics research and its application in healthcare. The bill also calls for expanded research into genetic and environmental interactions, particularly concerning minority populations, and seeks to improve the quality and availability of training for genetics and genomics professionals. Additionally, the legislation proposes a tax credit for research expenses related to developing specific diagnostic tests for drugs. It also intends to expand adverse event reporting to include those arising from genetic testing and to improve the safety and effectiveness of genetic tests themselves. The bill affects health professionals, researchers, and patients by aiming to improve the understanding and use of genetic information in healthcare. This bill was introduced in the Senate in August 2006 and is currently in the committee phase. Further action would require it to be reported out of committee, passed by both the Senate and the House of Representatives, and then signed into law by the President.
- Has S. 3822 become law?
- The source does not supply a confirmed lifecycle stage for S. 3822. Check the latest action and official source below.
- Who sponsored S. 3822?
- S. 3822 was sponsored by Sen. Obama, Barack [D-IL] (D-IL), with 0 cosponsors.
- What's the latest action on S. 3822?
- Read twice and referred to the Committee on Finance. (3 Aug 2006).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Sen. Obama, Barack [D-IL]
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.